MAX-40279

MAX-40279 is a dual and orally active inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 is also effective against the FLT3 mutants such as FLT3D835Y, suggesting that it can overcome resistance to Quizartinib (HY-13001) and Sorafenib (HY-10201) . MAX-40279 inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT) . MAX-40279 can be used for the research of acute myelogenous leukemia (AML) [1][2][3].

Product Specifications

CAS Number

[2070931-57-4]

UNSPSC

12352005

Target

FGFR; FLT3

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/max-40279.html

Purity

97.04

Solubility

DMSO : ≥ 25 mg/mL

Smiles

FC1=CC(OC)=C(C2=C(C)SC3=C2N=C(NC4=CN(C5CCNCC5)N=C4)N=C3)C=C1

Molecular Formula

C22H23FN6OS

Molecular Weight

438.52

References & Citations

[1]Yuguang Wang, et al. Novel Therapeutic Methods. Patent WO2021180032A1.|[2]Yuguang Wang, et al. Preclinical Evaluation of MAX-40279, a FLT3/FGFR Dual Kinase Inhibitor for Treatment of Acute Myeloid Leukemia, Blood, Volume 132, Supplement 1, 2018.|[3]Xue Z, et al. PIM1 instigates endothelial-to-mesenchymal transition to aggravate atherosclerosis. Theranostics. 2025 Jan 1;15 (2) :745-765.